Last reviewed · How we verify
Relmacabtagene autoleucel and transplantation
Relmacabtagene autoleucel and transplantation is a Small molecule drug developed by Zhengzhou University. It is currently in Phase 1 development.
At a glance
| Generic name | Relmacabtagene autoleucel and transplantation |
|---|---|
| Sponsor | Zhengzhou University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors (PHASE2)
- Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Relmacabtagene autoleucel and transplantation CI brief — competitive landscape report
- Relmacabtagene autoleucel and transplantation updates RSS · CI watch RSS
- Zhengzhou University portfolio CI
Frequently asked questions about Relmacabtagene autoleucel and transplantation
What is Relmacabtagene autoleucel and transplantation?
Relmacabtagene autoleucel and transplantation is a Small molecule drug developed by Zhengzhou University.
Who makes Relmacabtagene autoleucel and transplantation?
Relmacabtagene autoleucel and transplantation is developed by Zhengzhou University (see full Zhengzhou University pipeline at /company/zhengzhou-university).
What development phase is Relmacabtagene autoleucel and transplantation in?
Relmacabtagene autoleucel and transplantation is in Phase 1.